Day: January 23, 2025

        Company Announcement No 04/2025Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk23 January 2025  Dear Sirs Sydbank A/S share buyback programme completed – transactions in week 04 Sydbank’s share buyback programme of DKK 1,200m which was announced on 28 February 2024 and scheduled to end on or before 31 January 2025 has been completed. Under the programme 3,383,960 own shares were repurchased at a transaction value of approx DKK 1,200m during the period up to termination. The purpose of the share buyback programme was to reduce the share capital of Sydbank and the programme was executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation...

Serie A1 women 2024/25 match between UYBA Eurotek Volley Busto Arsizio (red) and Bartoccini-Mc Restauri Perugia (black) at E-Work ArenaBUSTO ARSIZIO, ITALY – Serie A1 women 2024/25 match between UYBA Eurotek Volley Busto Arsizio (red) and Bartoccini-Mc Restauri Perugia (black) at E-Work ArenaBUSTO ARSIZIO, ITALY – Serie A1 women 2024/25 match between UYBA Eurotek Volley Busto Arsizio (red) and Bartoccini-Mc Restauri Perugia (black) at E-Work ArenaDublin, Ireland, and Milan, Italy, Jan. 23, 2025 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera Holdings”) (Nasdaq: BREA), an Ireland-based, Nasdaq-listed, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, is pleased to provide...

SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows: To our valued shareholders, As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment. Last year was vital for Atossa as we continued to demonstrate the broad utility of (Z)-endoxifen as an innovative therapy that has the potential to transform the breast cancer treatment...

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) — Willis, a WTW business (Nasdaq: WTW), is pleased to announce that its Investment Management Insurance (IMI) Plus product is now available to U.S. clients. Previously launched in July 2024 for clients in the UK and Canada, this unified management and professional policy addresses the specific needs of asset managers, providing integrated protection and streamlined management across key risk categories. IMI Plus grants critical coverages—cyber liability, employment practices liability (EPL), directors’ and officers’ (D&O) liability, errors and omissions (E&O) liability, and crime—under one cohesive offering. By consolidating these coverages into one policy, asset managers can reduce administrative complexity while enhancing operational efficiency. The policy’s key benefits include:Multiple...

JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class,...

News Release January 23, 2025 BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today their publication of reference intervals using BioPorto’s NGAL immunoassay in healthy adult and pediatric individuals. The study was published in Diagnostics, an international, open-access, peer-reviewed journal and provides clinicians with a standardized comparison to evaluate NGAL levels ensuring broad clinical applicability in their patients. The publication of the reference range study results will be used by laboratories implementing NGAL assays from BioPorto as a baseline of healthy patient populations, a required...

All amounts expressed in US dollars unless stated otherwise BULYANHULU, Tanzania, Jan. 23, 2025 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD) (TSX:ABX) has injected over $4.24 billion into the Tanzanian economy since establishing the Twiga joint venture with the government in 2019, contributing $888 million in 2024 alone. Twiga comprises the North Mara and Bulyanhulu gold mines. At a media briefing here today, Barrick president and chief executive Mark Bristow said the Twiga partnership remained a leader in Tanzania’s extractive industry, creating thousands of jobs, supporting local businesses and funding critical community projects. “We spent $573 million on national suppliers and service providers last year, representing about 83% of our total spend in-country. Additionally, 75% of all our payments to suppliers and...